– Voyager’s TRACERTM capsid platform validated by Pfizer option exercise – – Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER – – Pipeline programs advancing; development candidate selections for lead programs expected Q4 2022 to H1 2023 – – Conference call at 8:30 a.m. ET today – […]